Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEAN(a)-CCTA: Olpasiran effect on coronary artery plaque burden in ASCVD with elevated lipoprotein(a)
2025-521117-88-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Dec 2025
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease, myocardial infarction (MI) and coronary arteriosclerosis comparing Olpasiran with Placebo (2 arms). Primary endpoint: Change in non-calcified plaque volume from baseline to week 72. Planned start Dec 2025; status: authorised.
02
Drugs
olpasiran
03
Conditions
atherosclerotic diseasemyocardial infarction (MI)coronary arteriosclerosis
Beyond the preview
Go deeper on 2025-521117-88-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521117-88-00.